Pouneh K Fazeli1, Jonathan G Teoh2, Eleanor L Lam3, Anu V Gerweck4, Tamara L Wexler3, Eliza P Teo2, Brian M Russell4, Ronen Durst2, David McCarty2, Rory B Weiner2, Michael H Picard2, Anne Klibanski3, Karen K Miller3. 1. Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA 02114, United States; Harvard Medical School, Boston, MA 02115, United States. Electronic address: pkfazeli@partners.org. 2. Division of Cardiology, Massachusetts General Hospital, Boston, MA 02114, United States; Harvard Medical School, Boston, MA 02115, United States. 3. Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA 02114, United States; Harvard Medical School, Boston, MA 02115, United States. 4. Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA 02114, United States.
Abstract
OBJECTIVE: Although growth hormone (GH) replacement is prescribed for patients with hypopituitarism due to many etiologies, it is not routinely prescribed for patients with GH deficiency (GHD) after cure of acromegaly (acroGHD). This study was designed to investigate the effect of GH replacement on cardiac parameters in acroGHD. DESIGN: We prospectively evaluated for 12months 23 patients with acroGHD: 15 subjects on GH replacement and eight subjects not on GH replacement. Main outcome measures included LV mass corrected for body surface area (LVM/BSA) and measures of diastolic dysfunction (E/A ratio and deceleration time), as assessed by echocardiography. RESULTS: After 12months of follow-up, there were no differences between the GH-treated group and the untreated group in LVM/BSA (GH: 74.4±22.5g/m(2) vs untreated: 72.9±21.3g/m(2), p=0.89), E/A ratio (GH: 1.21±0.39 vs untreated: 1.08±0.39, p=0.50) or deceleration time (GH: 224.5±60.1ms vs untreated: 260±79.8ms, p=0.32). The overall degree of diastolic function was similar between the groups with 42.9% of untreated subjects and 50% of GH-treated subjects (p=0.76) classified as having normal diastolic function at follow-up. CONCLUSIONS: There were no significant differences in LVM/BSA or parameters of diastolic function in patients with a history of acromegaly treated for GHD as compared to those who were untreated. These data are reassuring with respect to cardiovascular safety with GH use after treatment for acromegaly, although further longer term study is necessary to evaluate the safety and efficacy of GH treatment in this population.
OBJECTIVE: Although growth hormone (GH) replacement is prescribed for patients with hypopituitarism due to many etiologies, it is not routinely prescribed for patients with GH deficiency (GHD) after cure of acromegaly (acroGHD). This study was designed to investigate the effect of GH replacement on cardiac parameters in acroGHD. DESIGN: We prospectively evaluated for 12months 23 patients with acroGHD: 15 subjects on GH replacement and eight subjects not on GH replacement. Main outcome measures included LV mass corrected for body surface area (LVM/BSA) and measures of diastolic dysfunction (E/A ratio and deceleration time), as assessed by echocardiography. RESULTS: After 12months of follow-up, there were no differences between the GH-treated group and the untreated group in LVM/BSA (GH: 74.4±22.5g/m(2) vs untreated: 72.9±21.3g/m(2), p=0.89), E/A ratio (GH: 1.21±0.39 vs untreated: 1.08±0.39, p=0.50) or deceleration time (GH: 224.5±60.1ms vs untreated: 260±79.8ms, p=0.32). The overall degree of diastolic function was similar between the groups with 42.9% of untreated subjects and 50% of GH-treated subjects (p=0.76) classified as having normal diastolic function at follow-up. CONCLUSIONS: There were no significant differences in LVM/BSA or parameters of diastolic function in patients with a history of acromegaly treated for GHD as compared to those who were untreated. These data are reassuring with respect to cardiovascular safety with GH use after treatment for acromegaly, although further longer term study is necessary to evaluate the safety and efficacy of GH treatment in this population.
Authors: Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista Journal: J Am Soc Echocardiogr Date: 2009-02 Impact factor: 5.251
Authors: A Frustaci; C Chimenti; M Setoguchi; S Guerra; S Corsello; F Crea; A Leri; J Kajstura; P Anversa; A Maseri Journal: Circulation Date: 1999-03-23 Impact factor: 29.690
Authors: Catherine Beauregard; Andrea L Utz; Amber E Schaub; Lisa Nachtigall; Beverly M K Biller; Karen K Miller; Anne Klibanski Journal: J Clin Endocrinol Metab Date: 2008-04-01 Impact factor: 5.958
Authors: C L Ronchi; C Giavoli; E Ferrante; E Verrua; S Bergamaschi; D I Ferrari; S Corbetta; L Montefusco; M Arosio; B Ambrosi; A Spada; P Beck-Peccoz Journal: Eur J Endocrinol Date: 2009-04-07 Impact factor: 6.664
Authors: Sideris P Delaroudis; Zoe A Efstathiadou; George N Koukoulis; Marina D Kita; Dimitrios Farmakiotis; Ourania G Dara; Dimitrios G Goulis; Areti Makedou; Pantelis Makris; Aris Slavakis; Avraam I Avramides Journal: Clin Endocrinol (Oxf) Date: 2008-01-10 Impact factor: 3.478
Authors: Agata Popielarz-Grygalewicz; Jakub S Gąsior; Aleksandra Konwicka; Paweł Grygalewicz; Maria Stelmachowska-Banaś; Wojciech Zgliczyński; Marek Dąbrowski Journal: Int J Endocrinol Date: 2018-07-11 Impact factor: 3.257